Skip to content
NYSE · LABORATORY ANALYTICAL INSTRUMENTS · LARGE CAP

Bio-rad Laboratories, Inc. BIO-B

18 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.6B
▲ 0.7% YoY
$759.9M
$374.6M
▲ 29.4% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Bio-Rad Laboratories, Inc. is a multinational life science and clinical diagnostics company that develops, manufactures, and markets a broad portfolio of instruments, systems, reagents, and consumables. It maintains direct operations in over 36 countries outside the United States through subsidiaries focused on sales, customer service, and product distribution. Bio-Rad operates in two industry segments, Life Science and Clinical Diagnostics, both of which operate worldwide. As of December 31, 2025, the company had approximately 7,450 employees, most of them full-time, with roughly 46% based in the Americas, 36% in Europe, the Middle East and Africa, and 18% in Asia Pacific, working in 37 different countries. As of December 31, 2025, it employed approximately 790 people worldwide in research and development, including degreed scientists, engineers, software developers and other technical support staff.

Written from the business description in BIO-RAD LABORATORIES, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 13 February 2026. Every sentence was checked against that document before publication.

Growth

USD 2.6B
Revenue, FY2025 · full 18-year series below
Revenue $B Net income $B
FY2025 · Revenue 2.6 · Net income 0.8
2B3B-2B-3B
2008201120142017202020232025
Compound annual growth
−2.7%
+0.3%
+2.5%
+2.0%
−27.6%
+21.4%
+9.9%
−26.1%
+22.3%
+10.1%
+11.7%
+26.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +0.3% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

29 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 1.8% · Net 29.4%
50%100%-50%-100%
200820162025
ROE
FY2025 · ROE 10.8%
20%40%-10%-20%-30%
200820162025
Three returns, three denominators.

Each USD of equity produced 11 cents of profit this year.

Cash & shareholders

USD 295.5M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 374.6
200M400M
200820162025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks 295.5
200M400M
201020122014201620182020202220242025

USD 295.5M in buybacks — 39% of the year's profit went back to shareholders.

Total assetsUSD 10.6B
EquityUSD 7.5B
CashUSD 529.8M
Gross debtUSD 1.2B
Net debtUSD 671.9M
Current ratio5.62×

Net debt stands at 9% of equity.

The 18-year record

18 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
BIO-B, 18-year financial record
Metric 202520242023202220212020201920182017201620152014201320122011201020092008
Revenue $B2.62.62.72.82.92.52.32.32.22.12.02.22.12.12.11.91.81.8
Operating income $B0.00.30.30.50.50.40.2−0.10.10.10.20.10.20.30.30.30.20.2
EBITDA $B0.20.40.50.60.60.60.40.00.30.20.30.30.30.40.40.40.3◌
Income tax $B0.2−0.5−0.2−1.11.21.10.50.1−0.00.00.00.00.00.10.10.00.00.0
Net income $B0.8−1.8−0.6−3.64.33.81.80.40.10.00.10.10.10.20.20.20.10.1
Free cash flow $B0.40.30.20.10.50.50.40.2−0.00.10.10.20.10.10.20.10.30.3
EPS, diluted $27.85−65.36−21.82−121.79140.83126.4758.2712.104.070.883.713.052.695.786.296.595.203.24
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————————————
ROE %10.8−24.1−6.9−31.136.148.836.010.54.41.04.74.13.78.810.913.312.48.4
Shares out B◌0.010.010.010.010.010.010.010.010.010.010.010.010.010.010.01◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 88 reconciliationsAUDITED

Reconciled in 18 of the 18 fiscal years we could check. Four checks were skipped: the balance sheet is not tagged before 2009. One check was skipped: EPS is not tagged before 2008. One check was skipped: revenue is not tagged before 2008.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityLaboratory Analytical Instruments
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2008

Share this section

Download image